RAAS Inhibitor Drugs in Dialysis Patients

• Status: Unknown status
• Trial end date: 2012-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Hypertensive haemodialysis patients are at high risk for cardiovascular events. This study was undertaken to ascertain whether the upstream of aliskirne, a direct renin inhibitor improves mortality and cardiovascular outcomes in these high-risk population.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Second University of Naples; University of Campania "Luigi Vanvitelli"
• Collaborator: IRCCS San Raffaele

Criteria

Inclusion Criteria:

• chronic kidney disease stage 5

• undergoing maintenance haemodialysis for a minimum of 3 months

• existing arterial hypertension or

• history of arterial hypertension or

• resting blood pressure ≥140/90 mmHg or

• antihypertensive medication

• man and female

• 18 years and older.

Exclusion Criteria:

• recent myocardial infarction (less than 3 months)

• atrial fibrillation/atrial flutter

• hypotension with systolic blood pressure of <90 mmHg

• high-grade aortic stenosis

• left ventricular ejection fration <50%

• known allergy to aliskiren

• severe disorders of liver function